Top

Published in:

01-12-2020 | Metastasis | Original Article

Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy

Authors: Jie-ying Liang, Shao-yan Xi, Qiong Shao, Yun-fei Yuan, Bin-kui Li, Yun Zheng, De-shen Wang, Xiao-jun Wu, Pei-rong Ding, Gong Chen, Li-ren Li, Feng-hua Wang, Zhi-qiang Wang, Zhi-zhong Pan, Rui-hua Xu, Yu-hong Li

Published in: Cancer Immunology, Immunotherapy | Issue 12/2020

Abstract

Various scoring systems have been proposed to predict the postoperative prognosis of colorectal liver metastasis (CRLM), including the clinical risk score (CRS), the immunoscore and so on. Recently, histopathological growth patterns (HGPs) have been recognized. However, the correlation between HGPs and the immunoscore, and their prognostic values in patients with CRLM after liver resection remain undetermined. In this study, HGPs were retrospectively evaluated in H&E-stained slides from 166 CRLM patients. The immunoscore was calculated according to the densities of immunostained CD3 + and CD8 + cells. A risk score combining HGPs, the immunoscore and the CRS was defined and divided patients into the low-, medium- and high-risk group. Our results showed that the densities of CD3 + and CD8 + cells were higher in the desmoplastic HGP (dHGP) group than in the non-dHGP group, and the proportion of high immunoscores was also higher in the dHGP group (51.9% vs. 33.0%, respectively, P = 0.020). Patients with the dHGP had significantly longer relapse-free survival (RFS) and overall survival (OS) than those with the non-HGP. The low-risk group showed significantly higher 2-year RFS and 5-year OS rates than the other two groups (RFS: 76.2%, 43.7% and 33.1%, respectively; P < 0.001; OS: 89.7%, 54.4% and 33.3%, respectively; P < 0.001). In conclusion, the dHGP correlates with relatively high immunoscores, predicting a favorable prognosis independent of the immunoscore and CRS. A novel risk score combining HGPs, the immunoscore and the CRS may be used for the stratification of CRLM patients’ survival.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492CrossRefPubMed

Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G (2006) A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg 93(4):465–474. https://doi.org/10.1002/bjs.5278CrossRefPubMed

Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235(6):759–766. https://doi.org/10.1097/00000658-200206000-00002CrossRefPubMedPubMedCentral

de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, Choti MA, Aldrighetti L, Capussotti L, Pawlik TM (2009) Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 250(3):440–448. https://doi.org/10.1097/SLA.0b013e3181b4539bCrossRefPubMed

Margonis GA, Buettner S, Andreatos N, Wagner D, Sasaki K, Barbon C, Beer A, Kamphues C, Loes IM, He J, Pawlik TM, Kaczirek K, Poultsides G, Lonning PE, Cameron JL, Mischinger HJ, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ (2019) Prognostic factors change over time after hepatectomy for colorectal liver metastases: a multi-institutional, international analysis of 1099 patients. Ann Surg 269(6):1129–1137. https://doi.org/10.1097/SLA.0000000000002664CrossRefPubMed

Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN (2005) Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241(5):715–722. https://doi.org/10.1097/01.sla.0000160703.75808.7ddiscussion 722–714CrossRefPubMedPubMedCentral

Zakaria S, Donohue JH, Que FG, Farnell MB, Schleck CD, Ilstrup DM, Nagorney DM (2007) Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg 246(2):183–191. https://doi.org/10.1097/SLA.0b013e3180603039CrossRefPubMedPubMedCentral

Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230(3):309–318. https://doi.org/10.1097/00000658-199909000-00004discussion 318–321CrossRefPubMedPubMedCentral

Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Borger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grutzmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Leonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Musina AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J (2018) International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391(10135):2128-2139. https://doi.org/10.1016/S0140-6736(18)30789-X

10.

Mlecnik B, Van den Eynde M, Bindea G, Church SE, Vasaturo A, Fredriksen T, Lafontaine L, Haicheur N, Marliot F, Debetancourt D, Pairet G, Jouret-Mourin A, Gigot JF, Hubert C, Danse E, Dragean C, Carrasco J, Humblet Y, Valge-Archer V, Berger A, Pages F, Machiels JP, Galon J (2018) Comprehensive intrametastatic immune quantification and major impact of immunoscore on Survival. J Natl Cancer Inst 110(1):97–108. https://doi.org/10.1093/jnci/djx123CrossRef

11.

Wang Y, Lin HC, Huang MY, Shao Q, Wang ZQ, Wang FH, Yuan YF, Li BK, Wang DS, Ding PR, Chen G, Wu XJ, Lu ZH, Li LR, Pan ZZ, Sun P, Yan SM, Wan DS, Xu RH, Li YH (2018) The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases. Cancer Immunol Immunother 67(3):435–444. https://doi.org/10.1007/s00262-017-2094-8CrossRefPubMed

12.

Frentzas S, Simoneau E, Bridgeman VL, Vermeulen PB, Foo S, Kostaras E, Nathan M, Wotherspoon A, Gao ZH, Shi Y, Van den Eynden G, Daley F, Peckitt C, Tan X, Salman A, Lazaris A, Gazinska P, Berg TJ, Eltahir Z, Ritsma L, Van Rheenen J, Khashper A, Brown G, Nystrom H, Sund M, Van Laere S, Loyer E, Dirix L, Cunningham D, Metrakos P, Reynolds AR (2016) Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat Med 22(11):1294–1302. https://doi.org/10.1038/nm.4197CrossRefPubMedPubMedCentral

13.

van Dam PJ, van der Stok EP, Teuwen LA, Van den Eynden GG, Illemann M, Frentzas S, Majeed AW, Eefsen RL, Coebergh van den Braak RRJ, Lazaris A, Fernandez MC, Galjart B, Laerum OD, Rayes R, Grunhagen DJ, Van de Paer M, Sucaet Y, Mudhar HS, Schvimer M, Nystrom H, Kockx M, Bird NC, Vidal-Vanaclocha F, Metrakos P, Simoneau E, Verhoef C, Dirix LY, Van Laere S, Gao ZH, Brodt P, Reynolds AR, Vermeulen PB (2017) International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. Br J Cancer 117(10):1427–1441. https://doi.org/10.1038/bjc.2017.334CrossRefPubMedPubMedCentral

14.

Nielsen K, Rolff HC, Eefsen RL, Vainer B (2014) The morphological growth patterns of colorectal liver metastases are prognostic for overall survival. Mod Pathol 27(12):1641–1648. https://doi.org/10.1038/modpathol.2014.4CrossRefPubMed

15.

Eefsen RL, Vermeulen PB, Christensen IJ, Laerum OD, Mogensen MB, Rolff HC, Van den Eynden GG, Hoyer-Hansen G, Osterlind K, Vainer B, Illemann M (2015) Growth pattern of colorectal liver metastasis as a marker of recurrence risk. Clin Exp Metastasis 32(4):369–381. https://doi.org/10.1007/s10585-015-9715-4CrossRefPubMed

16.

Galjart B, Nierop PMH, van der Stok EP, van den Braak R, Hoppener DJ, Daelemans S, Dirix LY, Verhoef C, Vermeulen PB, Grunhagen DJ (2019) Angiogenic desmoplastic histopathological growth pattern as a prognostic marker of good outcome in patients with colorectal liver metastases. Angiogenesis 22(2):355–368. https://doi.org/10.1007/s10456-019-09661-5CrossRefPubMedPubMedCentral

17.

Brunner SM, Kesselring R, Rubner C, Martin M, Jeiter T, Boerner T, Ruemmele P, Schlitt HJ, Fichtner-Feigl S (2014) Prognosis according to histochemical analysis of liver metastases removed at liver resection. Br J Surg 101(13):1681–1691. https://doi.org/10.1002/bjs.9627CrossRefPubMed

18.

Eefsen RL, Engelholm L, Alpizar-Alpizar W, Van den Eynden GG, Vermeulen PB, Christensen IJ, Laerum OD, Rolff HC, Hoyer-Hansen G, Vainer B, Osterlind K, Illemann M (2015) Inflammation and uPAR-expression in colorectal liver metastases in relation to growth pattern and neo-adjuvant therapy. Cancer Microenviron 8(2):93–100. https://doi.org/10.1007/s12307-015-0172-zCrossRefPubMedPubMedCentral

19.

van Dam PJ, Daelemans S, Ross E, Waumans Y, Van Laere S, Latacz E, Van Steen R, De Pooter C, Kockx M, Dirix L, Vermeulen PB (2018) Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy. Semin Cancer Biol 52(Pt 2):86–93. https://doi.org/10.1016/j.semcancer.2018.01.009CrossRefPubMed

20.

Lazaris A, Amri A, Petrillo SK, Zoroquiain P, Ibrahim N, Salman A, Gao ZH, Vermeulen PB, Metrakos P (2018) Vascularization of colorectal carcinoma liver metastasis: insight into stratification of patients for anti-angiogenic therapies. J Pathol Clin Res 4(3):184–192. https://doi.org/10.1002/cjp2.100CrossRefPubMedPubMedCentral

21.

Stessels F, Van den Eynden G, Van der Auwera I, Salgado R, Van den Heuvel E, Harris AL, Jackson DG, Colpaert CG, van Marck EA, Dirix LY, Vermeulen PB (2004) Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer 90(7):1429–1436. https://doi.org/10.1038/sj.bjc.6601727CrossRefPubMedPubMedCentral

22.

Hegde PS, Wallin JJ, Mancao C (2018) Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol 52(Pt 2):117–124. https://doi.org/10.1016/j.semcancer.2017.12.002CrossRefPubMed

23.

Calon A, Tauriello DV, Batlle E (2014) TGF-beta in CAF-mediated tumor growth and metastasis. Semin Cancer Biol 25:15–22. https://doi.org/10.1016/j.semcancer.2013.12.008CrossRefPubMed

24.

Tang L, Yang J, Liu W, Tang X, Chen J, Zhao D, Wang M, Xu F, Lu Y, Liu B, Sun Q, Zhang L, He F (2009) Liver sinusoidal endothelial cell lectin, LSECtin, negatively regulates hepatic T-cell immune response. Gastroenterology 137(4):1498–1508. https://doi.org/10.1053/j.gastro.2009.07.051e1491–1495CrossRefPubMed

25.

Safadi R, Ohta M, Alvarez CE, Fiel MI, Bansal M, Mehal WZ, Friedman SL (2004) Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 127(3):870–882. https://doi.org/10.1053/j.gastro.2004.04.062CrossRefPubMed

26.

Parola M, Pinzani M (2019) Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med 65:37–55. https://doi.org/10.1016/j.mam.2018.09.002CrossRefPubMed

27.

Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA (2014) Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 14(3):181–194. https://doi.org/10.1038/nri3623CrossRefPubMed

28.

Nierop PMH, Galjart B, Hoppener DJ, van der Stok EP, Coebergh van den Braak RRJ, Vermeulen PB, Grunhagen DJ, Verhoef C (2019) Salvage treatment for recurrences after first resection of colorectal liver metastases: the impact of histopathological growth patterns. Clin Exp Metastasis 36(2):109–118. https://doi.org/10.1007/s10585-019-09960-7CrossRefPubMedPubMedCentral

29.

Berthel A, Zoernig I, Valous NA, Kahlert C, Klupp F, Ulrich A, Weitz J, Jaeger D, Halama N (2017) Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival. Oncoimmunology 6(3):e1286436. https://doi.org/10.1080/2162402X.2017.1286436CrossRefPubMedPubMedCentral

30.

Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, Gonen M, Jarnagin W, Fong Y, Blumgart L, D'Angelica M, DeMatteo RP (2009) T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol 16(9):2524–2530. https://doi.org/10.1245/s10434-009-0585-3CrossRefPubMed

31.

Vermeulen PB, Colpaert C, Salgado R, Royers R, Hellemans H, Van Den Heuvel E, Goovaerts G, Dirix LY, Van Marck E (2001) Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. J Pathol 195(3):336–342. https://doi.org/10.1002/path.966CrossRefPubMed

Title: Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy
Authors: Jie-ying Liang
Shao-yan Xi
Qiong Shao
Yun-fei Yuan
Bin-kui Li
Yun Zheng
De-shen Wang
Xiao-jun Wu
Pei-rong Ding
Gong Chen
Li-ren Li
Feng-hua Wang
Zhi-qiang Wang
Zhi-zhong Pan
Rui-hua Xu
Yu-hong Li
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keywords: Metastasis
Colorectal Cancer
Colorectal Cancer
Published in: Cancer Immunology, Immunotherapy / Issue 12/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-020-02632-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2020

Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis

The adjuvant effect of melanin is superior to incomplete Freund’s adjuvant in subunit/peptide vaccines in mice

Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies

Induction of systemic immune responses and reversion of immunosuppression in the tumor microenvironment by a therapeutic vaccine for cervical cancer

Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer

Anti-tumor efficacy of plasmid encoding emm55 in a murine melanoma model

Keynote webinar | Spotlight on antibody–drug conjugates in cancer